Brucella melitensis mutants and methods

Details Brucella melitensis mutants and methods Brucella melitensis mutants and methods

2009-10-15

2011-12-13

Duffy, Patricia A (Department: 1645)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093100, C424S252100, C435S252100

Reexamination Certificate

active

08075879

ABSTRACT:
Certain attenuated mutants ofBrucella, especiallyB. melitensis, B. abortus, B. suisandB. ovis, when administered to a human or animal trigger a protective immune response such that subsequent challenge with virulentBrucellaof the same species does not result in disease or results in much less severe symptoms. Functional inactivation of galE, a virB gene or the operon (ORFs 1087-1090) comprising the gene encoding β-hexosaminidase (BMEI1087) and a lytic murein transglycosylase gene (BMEI1088). A specific example of the attenuated galE mutant which produces a protective immune response isB. melitensisGR024. The specific example of an inactivated ORF1087-1090 operon isB. melitensisGR026; it has an insertion mutation in the promoter region upstream of ORF 1090. Vaccination with live cells of either or both of these mutants results in a T cell response which protects the human or animal against challenge with virulentB. melitensis. Similar strategies for protective immunity using live attenuated mutants are useful forB. abortus, B. suisandB. ovisas well.

REFERENCES:
patent: 5830702 (1998-11-01), Portnoy et al.
patent: WO 2005/084706 (2005-09-01), None
Alton et al. (1967) “Brucella melitensisVaccine. The Stability of the Degree of Attenuation,”J. Comp. Pathol. 77:293-300.
Anderson et al. (Apr. 2006) “CGHScan: Finding Variable Regions Using High-Density Microarray Comparative Genomic Hybridization Data,”BMC Genomics7:91-98.
Blasco, J.M. (1997) “A Review of the Use ofB. melitensisRev 1 Vaccine in Adult Sheep and Goats,” Prev. Vet. Med. 31:275-283.
Boschiroli et al. (Feb. 2002) “TheBrucella suisvirB Operon is Induced Intracellularly in Macrophages,”Proc. Nat. Acad. Sci. USA99:1544-1549.
Braun et al. (1947) “Independent Variation of Characteristics inBrucella abortusVariants and Their Detection,”Am. J. Vet. Res. 8:386-390.
Comerci et al. (2001) “Essential Role of the virB Machinery in the Maturation of theBrucella abortus-Containing Vacuole,”Cell. Microbiol. 3:159-168.
Contag et al. (1995) “Photonic Detection of Bacterial Pathogens in Living Hosts,”Mol. Microbiol. 18:593-603.
DelVecchio et al. (2002) “The Genome Sequence of the Facultative Intracellular PathogenBrucella melitensis,” Proc. Nat. Acad. Sci. USA99:443-448.
Elberg et al. (1957) “Immunization AgainstBrucellaInfection. VI. Immunity Conferred on Goats by a Nondependent Mutant from a Streptomycin-Dependent Mutant Strain ofBrucella melitensis,” J. Bacteriol. 73:211-217.
Fry et al. (2000) “ThegaIEGene ofCampylobacter jejuniis Involved in Lipopolysaccharide Synthesis and Virulence,”Infect. Immun. 68:2594-2601.
Grode et al. (Sep. 2005) “Increased Vaccine Efficacy Against Tuberculosis of RecombinantMycobacterium bovisBacile Calmette-Guerin Mutants that Secrete Listeriolysin,”J. Clin. Invest. 115(9):2472-2479.
Henderson et al. (Mar. 2001) “Virulence Functions of Autotransporter Proteins,”Infect. Immun. 69(3):1231-1243.
Hone et al. (1987) “Construction of DefinedgaIEMutants ofSalmonellafor Use as Vaccines,”J. Infect. Dis. 156:167-174.
Hong et al. (2000) “Identification of Genes Required for Chronic Persistence ofBrucella abortusin Mice,”Infect. Immun. 68:4102-4107.
Kimoto et al. (May 2003) “Differences in Gama Interferon Production Induced by Listeriolysin O and Ivanolysin O Result in Different Levels of Protective Immunity in Mice Infected withListeria monocytogenesandListeria ivanovii,” Infect. Immun. 71(5):2447-2454.
Ko et al. (2002) “Virulence Criteria forBrucella abortusStrains as Determined by Interferon Regulatory Factor 1-Deficient Mice,”Infect. Immun. 70:7004-7012.
Ko et al. (2003) “Molecular Host-Pathogen Interaction in Brucellosis: Current Understanding and Future Approaches to Vaccine Development for Mice and Humans,”Clin. Microbiol. Rev. 16:65-78.
Kovach et al. (1995) “Four New Derivatives of the Broad-Host-Range Cloning Vector pBBr1MCS, Carrying Different Antibiotic-Resistance Cassettes,”Gene166:175-176.
Lapaque et al. (2005) “BrucellaLipopolysaccharide Acts as a Virulence Factor,”Curr. Opin. Microbiol. 8:60-66.
Lestrate et al. (2000) “Identification and Characterization of in vivo Attenuated Mutants ofBrucella melitensis,” Mol. Microbiol. 38:543-551.
Maskell et al. (1992) “The gal Locus fromHaemophilus influenzae: Cloning, Sequencing and the Use of gal Mutants to Study Lipopolysaccharide,”Mol. Microbiol. 6:3051-3063.
Monreal et al. (Jun. 2003) “Characterization ofBrucela abortusO-Polysaccharide and Core Lipopolysaccharide Mutants and Demonstration that a Complete Core is Required for Rough Vaccines to be Efficient AgainstBrucella abortusandBrucella ovisin the Mouse Model,”Infect. Immun. 71:3261-3271.
Monriyon et al. (2004) “Rough Vaccines in Animal Brucellosis: Structural and Genetic Basis and Present Status,”Vet. Res. 35:1-38.
Moreno et al. (Jan. 8, 2002) “Brucella melitensis: A Nasty Bug with Hidden Credentials for Virulence,”Proc. Nat. Acad. Sci. USA99(10):1-3.
Pei et al. (Jun. 2004) “Brucella abortusRough Mutants are Cytopathic for Macrophages in Culture,”Infect. Immun. 72:440-450.
Petrovska et al. (1999) “Brucella melitensis16M: Characterization of thegaIEGene and Mouse Immunization Studies withgaIEDeficient Mutant,”Vet. Microbiol. 65:21-36.
Pierson et al. (Oct. 1996) “Identification of thegaIEGene and agaleEHomolog and Characterization of Their Roles in the Biosynthesis of Lipopolysaccharide in a Serotype O:8 Strain ofYersinia enterocolitica,” J. Bacteriol. 178:5916-5924.
Rajashekara et al. (2005) “Temporal Analysis of Pathogenic Events in Virulent and AvirulentBrucella melitensisInfections,”Cellular Microbiol. 10:149-1473.
Rajshekara et al. (Aug. 2004) “Comparative Whole-Genome Hybridization Reveals Genomic Islands inBrucellaSpecies,”J. Bacteriol. 186(15):5040-5051.
Rajashekara et al. (May 2006) “Attenuated BioluminescentBrucella melitensisMutants GR019 (virB4) , GR024 (gaIE) , and GR026 (BMEI1090-BMEI1091) Confer Protection in Mice,”Infect Immun. 74(5):2925-2936.
Rittig et al. (2003) “Smooth and Rough Lipopolysaccharide Phenotypes ofBrucellaInduce Different Intracellular Trafficking and Cytokine/Chemokine Release in Human Monocytes,”J. Leukoc. Biol. 74:1045-1055.
Robertson et al. (1993) “The Role ofgaIEin the Biosynthesis and Function of Gonococcal Lipopolysaccharide,”Mol. Microbiol. 8:891-901.
Schurig et al. (2002) “Brucellosis Vaccines: Past, Present and Future,”Vet. Microbiol. 90:479-496.
Scupham et al. (1997) “Isolation and Characterization of the UDP-glucose4′-epimerase-encoding Gene,gaIE, fromBrucella abortus2308,”Gene202:53-59.
Young, E.J. (1995) “An Overview of Human Brucellosis,”Clin. Infect. Dis. 21:283-289.
Prosecution History for parent application, U.S. Appl. No. 11/633,371.

Affiliated with

Also associated with

Rating

Brucella melitensis mutants and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Brucella melitensis mutants and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Brucella melitensis mutants and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4315584